INTERNATIONAL CANCER ADVOCACY NETWORK
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : m****a@a*****n.o*g
Mission Statement
ICAN, International Cancer Advocacy Network, assists cancer patients throughout the United States and in 82 countries abroad, with direct patient navigation, molecular profiling research, clinical trials matching services, and health information technology and patient empowerment tools. We are funding top laboratories working on rare cancer mutations. We aim to extend life with the highest attainable quality of life.
About This Cause
ICAN, International Cancer Advocacy Network, has been direct patient navigators for 29 years, handling 19,000 complex Stage IV cancer cases on a pan-tumor basis. We have a small but mighty staff, and we devote 93% of our functional expenses to Patient Program Services. https://askican.org ICAN is leading a global biomarker support group, the Exon 20 Group, focusing on EGFR exon 20 insertions and HER2 exon 20 insertions which are each diagnosed in lung cancer and in 25 other cancer types. Exon 20 insertion mutations disproportionately affect never-smokers, women, and Asian patients across the world. The Exon 20 Group is a 1500+ and growing network, established in 2017 under ICAN's umbrella by founding co-chairs Kevin M. Hanlon, a Syracuse, New York entrepreneur and his brother Robert T. Hanlon, PhD, a lecturer at MIT. The Exon 20 Group includes a diverse, multi-stakeholder coalition of patients, care partners, family members, leading thoracic oncologists and community-based medical oncologists, molecular pathologists, exon 20 scientists, and members of the biopharma industry and molecular profiling laboratories. The Exon 20 Group provides direct patient navigation, oncology nursing services, virtual meetings, a warm and wonderful social media community of 20-plus private Facebook subgroups plus Inspire, in addition to peer-to-peer counseling through our Angel Buddies Program. We are striving to turn two lethal mutations into chronic, manageable conditions by providing customized patient advocacy services worldwide to exon 20 insertion patients as well as funding major laboratories engaged in exon 20 resistance research. https://exon20group.org Please reach the Exon 20 Group on X at @ exon20group, and nearly 2000 follow us. We welcome your support at any level and are thrilled to be Platinum-rated on GuideStar.org--one of the first organizations to receive that new rating and to consistently achieve that rating each year. ICAN is five-star rated on Great Nonprofits and has achieved that status 14 years in a row, ending 2024 nationally in 4th place for the most 5-star rated cancer nonprofit organizations. Also under ICAN's umbrella is one of the most talked-about new additions to the War against Cancer: The Biomarker Collaborative, https://biomarkercollaborative.org The Biomarker Collaborative is an umbrella group of specific biomarker organizations per cancer as well as the relevant general cancer type organizations that a newly-diagnosed patient--or a patient who has just found out that the cancer has spread--needs to know about. ICAN also manages and leads the MET Crusaders (for patients diagnosed with either MET exon 14 skipping mutation; MET amplification; or MET overexpression). The MET Crusaders is the leading biomarker support group for MET-altered patients, their care partners, oncologists, molecular profiling laboratories, and biopharma members. https://metcrusaders.org Please reach us on X at @ metcrusaders